In this article you will learn about the role of robust device design in improving the performance of orally inhaled products (OIPs) and supporting better patient outcomes. Copley Scientific Applications Specialist, Dr Clair Brooks, explores how patient behaviour, inhaler technique and day-to-day use can influence drug delivery, and explains how targeted testing can help developers better understand and mitigate these effects. The article also considers regulatory expectations for robustness testing and the value of more clinically representative methods, including studies of exhalation through dry powder inhalers.
This article is taken from ONdrugDelivery, Issue 170, 2025, pages 58–62. Copyright © 2025 Furness Publishing Ltd.
